Research & Development

Tokyo New Drug Research Laboratories and Fuji Laboratory are the core centres for Kowa Company Ltd.'s research and development activities in Japan and globally.

At the Tokyo New Drug Research Laboratories we conduct extensive research activities, including searching for new materials and product opportunities and their biological screening, molecular design, and preclinical studies such as biokinetic studies of medicine.

At the Fuji Laboratory we have two research divisions: 1) safety research and drug formulation research, and

2) research on drug delivery systems for efficiently delivering drugs to the target site, development of new dosage forms, development of over-the-counter drugs, and production of investigational agents.

In Europe, Kowa Research Europe, Ltd. take responsibility for the clinical development of Kowa Company Ltd.'s new products.

For more information on our research and development programmes please visit www.kowa.com

Target Areas of R&D

Lifestyle-related diseases

Dyslipidemia

Type 2 Diabetes

Arteriosclerotic disease

Immunity inflammation

Cancer

Inflammatory disease

Skin disease

Sensory organ diseases

Eye disease

Equilibrium and auditory function disorders

Pipeline Last updated: April 2017

Lifestyle-related diseases
Development Code/Generic Name (Administration)

K-877 / Pemafibrate

K-877-FL / Pemafibrate

K-877-BC / Pemafibrate

CSG452 / Tofogliflozin

SK-0403 / Anagliptin

Country/ Region

US

EU

Japan

Japan

US

EU

US

EU

Stage

PIII

PIII

PII

PI

PII

PII

PII

PII

Indications

Dyslipidemia

Non-alcoholic fatty liver/
Non-alcoholic steatohepatitis

Primary billiary cholangitis

Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Category

Selective PPARα Modulator

Selective PPARα
Modulator

Selective PPARα
Modulator

SGLT2 inhibitor

DPP-4 inhibitor 

Immunity inflammation
Development Code/Generic Name (Administration)

NIK-333, K-333 / Peretinoin

K-285/ Indometacin,
ℓ-menthol

Country/ Region

Japan

Asia

EU

US

Stage

PIII

PIII

PI

PI

Indications

Prevention of Recurrence of Liver Cancer

Acute pain

Category

Apoptosis inducer

NSAIDs

Sensory organ diseases
Development Code/Generic Name (Administration)

K-115-R /
Ripasudil hydrochloride hydrate

K-161

Country/ Region

Japan

US

Stage

PII

PII

Indications

Diabetic Retinopathy

Dry Eye

Category

Rho kinase inhibitor

 

Other
Development Code/Generic Name (Administration)

K-828-SP /
Sodium Valproate

K-163-SZ /
Pyridoxamine

K-755

K-134

Country/ Region

Japan

Japan

Japan
US

 

Stage

PIII

PII

PI

Preparing

Indications

Spinal Muscular Atrophy

Schizophrenia

 

Under consideration

Category

 

 

 

PDE3 inhibitor

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. Find out more.

X